Literature DB >> 20375592

Genetic variation in Toll-like receptor signalling and the risk of inflammatory and immune diseases.

Sinead C Corr1, Luke A J O'Neill.   

Abstract

There has been growing interest in the role of host genetic factors in humans and susceptibility to infectious and inflammatory diseases. Genetic variation in Toll-like receptors (TLRs), key innate immune receptors or their signalling molecules, have been described. Variation in certain TLRs has been linked to disease susceptibility. This genetic variation can result in an altered immune response to pathogenic challenge as well as exorbitant immune activation and inflammation, and thus may influence the pathogenesis or outcome of disease. Examples include variants of TLR4 in sepsis, malaria, inflammatory bowel disease and atherosclerosis; variants in TLR2 in tuberculosis and asthma; a variant in Mal (a key signal for TLR2 and TLR4) in malaria, tuberculosis and systemic lupus erythematosus; and variants in the kinase IRAK4 in pyogenic infections. These associations provide us with a validation for the role of TLRs in human disease, and also suggest possible strategies to limit or boost TLR function in the effort to develop new therapies. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20375592     DOI: 10.1159/000200774

Source DB:  PubMed          Journal:  J Innate Immun        ISSN: 1662-811X            Impact factor:   7.349


  17 in total

1.  Investigation of the differential potentials of TLR agonists to elicit uveitis in mice.

Authors:  Jordan J Allensworth; Stephen R Planck; James T Rosenbaum; Holly L Rosenzweig
Journal:  J Leukoc Biol       Date:  2011-09-20       Impact factor: 4.962

2.  Mannose-binding lectin and Toll-like receptor polymorphisms and Chagas disease in Chile.

Authors:  Thomas Weitzel; Inés Zulantay; Ina Danquah; Lutz Hamann; Ralf R Schumann; Werner Apt; Frank P Mockenhaupt
Journal:  Am J Trop Med Hyg       Date:  2012-02       Impact factor: 2.345

3.  Coding variants of TLR2 and TLR4 genes do not substantially contribute to prosthetic joint infection.

Authors:  Frantisek Mrazek; Jiri Gallo; Anna Stahelova; Martin Petrek
Journal:  Inflamm Res       Date:  2013-02-17       Impact factor: 4.575

Review 4.  Effects of air pollutants on innate immunity: the role of Toll-like receptors and nucleotide-binding oligomerization domain-like receptors.

Authors:  Rebecca N Bauer; David Diaz-Sanchez; Ilona Jaspers
Journal:  J Allergy Clin Immunol       Date:  2012-01       Impact factor: 10.793

Review 5.  Toll-like receptor polymorphisms, inflammatory and infectious diseases, allergies, and cancer.

Authors:  Andrei E Medvedev
Journal:  J Interferon Cytokine Res       Date:  2013-05-15       Impact factor: 2.607

6.  Distinct signaling pathways regulate TLR2 co-stimulatory function in human T cells.

Authors:  Nicole M Chapman; Mahmood Y Bilal; Noemi Cruz-Orcutt; Cory Knudson; Sofia Madinaveitia; Jonathan Light; Jon C D Houtman
Journal:  Cell Signal       Date:  2012-12-05       Impact factor: 4.315

7.  Toll-like receptors in autoimmunity with special reference to systemic lupus erythematosus.

Authors:  Vandana D Pradhan; Swaptagni Das; Prathamesh Surve; Kanjaksha Ghosh
Journal:  Indian J Hum Genet       Date:  2012-05

8.  Understanding the expression of Toll-like receptors in Asian Indians predisposed to coronary artery disease.

Authors:  Arindam Maitra; Jayashree Shanker; Debabrata Dash; Prathima Arvind; Vijay V Kakkar
Journal:  Arch Med Sci       Date:  2011-11-08       Impact factor: 3.318

9.  The Role of TLR2 in Infection and Immunity.

Authors:  Laura Oliveira-Nascimento; Paola Massari; Lee M Wetzler
Journal:  Front Immunol       Date:  2012-04-18       Impact factor: 7.561

10.  Single nucleotide polymorphisms in pathogen recognition receptor genes are associated with susceptibility to meningococcal meningitis in a pediatric cohort.

Authors:  Gijs Th J van Well; Marieke S Sanders; Sander Ouburg; Vinod Kumar; A Marceline van Furth; Servaas A Morré
Journal:  PLoS One       Date:  2013-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.